Last reviewed · How we verify
NCT07490444
Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome
Phase 2 trial testing Metric-optimized spectacles in Refractive Error Correction in 24 participants. Not yet recruiting.
1 December 2027
Quick facts
| Lead sponsor | Ohio State University |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 13 April 2026 |
| Primary completion | 1 December 2027 |
| Estimated completion | 1 May 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Metric-optimized spectacles
- Routine Clinical Spectacles
Conditions studied
- Refractive Error Correction — all drugs for Refractive Error Correction →
- Visual Acuity — all drugs for Visual Acuity →
Sponsor
Ohio State University
Who can join
Adults 5 to 12, any sex, with Refractive Error Correction or Visual Acuity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study seeks to determine whether glasses prescriptions determined from computer analysis of detailed images of the eyes provide better vision outcomes for children with Down syndrome than prescriptions determined using routine clinical methods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07490444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Refractive Error Correction
Currently open trials in the same condition.
- NCT07046065 — Algorithm-assisted Subjective Refraction Program Dedicated to Children · NA · recruiting
Other Ohio State University trials
Trials by the same sponsor.
- NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
- NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
- NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
- NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
- NCT07339163 — Efficacy of Booster Injection With Gardasil-9 Vaccine on Intersurgical Interval* for Adults With Recurrent Respiratory P · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07490444 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University
- Last refreshed: 24 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07490444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing